Observational Study With InnoLet® in Daily Clinical Practice

Completed

• Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2
• Interventions: Drug: insulin human

• Registration Number: NCT01492959
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03-23
• Primary Completion: 2005-03-23
• Study Completion: 2005-03-23
• Study First Submitted: 2011-12-09
• Study First Submitted QC: 2011-12-13
• Study First Posted: 2011-12-15
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-27
• Last Update Posted: 2017-02-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1030

Inclusion Criteria

• Diabetes mellitus (Type 1 or type 2)
• Need insulin treatment

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Insulin human	insulin human	-

Primary Outcome Measures

Name	Time	Method
Change in HbA1c (glycosylated haemoglobin)

Secondary Outcome Measures

Name	Time	Method
Adverse events: Serious and non-serious

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇰🇷 Seoul, Korea, Republic of